- Report
- October 2024
- 100 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- November 2024
- 70 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- April 2025
- 250 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 250 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- December 2024
- 175 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- August 2024
- 140 Pages
Global
From €2729EUR$2,999USD£2,340GBP
- Report
- May 2024
- 128 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 136 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 135 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- June 2024
- 206 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- May 2021
- 50 Pages
China
From €2366EUR$2,600USD£2,029GBP
- Report
- October 2022
- 72 Pages
China
From €3049EUR$3,350USD£2,614GBP
- Report
- October 2022
- 82 Pages
Asia Pacific
From €3413EUR$3,750USD£2,926GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1138EUR$1,250USD£975GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,146GBP
- Report
- March 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,238GBP
- Report
- September 2022
- 283 Pages
Global
From €6826EUR$7,500USD£5,852GBP

Actemra (tocilizumab) is a monoclonal antibody used to treat immune disorders, such as rheumatoid arthritis, giant cell arteritis, and systemic juvenile idiopathic arthritis. It works by blocking the action of interleukin-6, a protein that plays a role in inflammation. Actemra is approved for use in adults and children, and is administered intravenously or subcutaneously.
The Actemra market is a subset of the larger immune disorders drugs market. It is a growing market, driven by the increasing prevalence of autoimmune diseases and the need for effective treatments. Actemra is a key player in this market, as it is the only approved treatment for certain conditions, such as giant cell arteritis.
Companies in the Actemra market include Roche, which manufactures and markets the drug, as well as other pharmaceutical companies that develop and market treatments for immune disorders. Show Less Read more